Table 2.
Univariate and Multivariate Predictors of SVR12 in Patients Treated with Simeprevir Plus Sofosbuvir
| Baseline Covariate | All Patients (n=160) | |||||
|---|---|---|---|---|---|---|
| Univariate* | Multivariate 1§ ¶ | Multivariate 2§ $ | ||||
| OR (95% CI) | p-value | OR (95% CI) | p-value | OR (95% CI) | p-value | |
| CP-B/C cirrhosis | 0.26 (0.11–0.65) | <0.01 | 0.27 (0.09–0.80) | 0.02 | -- | -- |
| Total bilirubin ≥1.3 mg/dL | 0.45 (0.19–1.068 | 0.07 | -- | -- | -- | -- |
| Albumin ≥ 3.5 g/dL | 5.25 (1.95–14.1) | <0.01 | -- | -- | 4.17 (1.44–11.8) | 0.01 |
| Platelets ≥ 100 K/mm3 | 2.73 (1.06–7.01) | 0.04 | 2.19 (1.17–6.45) | 0.02 | 2.42 (1.09–7.12) | 0.04 |
| Any hepatic encephalopathy | 0.41 (0.16–1.04) | 0.06 | -- | -- | -- | -- |
| Any ascites | 0.47 (0.19–1.18) | 0.11 | -- | -- | -- | -- |
| MELD, per 1 unit | 0.90 (0.77–1.04) | 0.15 | -- | -- | -- | -- |
Univariate results of variables with p<0.20. Baseline covariates examined included age, sex, race/ethnic group (White, non-Hispanic vs. Hispanic vs. Black vs. Asian vs. Other), HCV genotype 1a (vs. 1b or other), HCV treatment experienced (vs. no treatment), laboratory indices [bilirubin, creatinine, international normalized ratio (INR), albumin and platelet count], CP class (CP-B/C vs. CP-A), MELD, HCV viral load, log-transformed (VL) and presence/absence of varices.
Adjusted for sex, race and center effect
Multivariate model 1 with CP-B/C cirrhosis included in the model
Multivariate model 2 without CP-B/C cirrhosis included in the model
CP = Child-Pugh, HCV = hepatitis C virus, MELD = model for end-stage liver disease, RNA = ribonucleic acid, SVR12 = sustained virologic response at 12 weeks